Evaluation of Dihydroxyanthracenedione (DHAD) in Advanced Prostate Cancer

Mitoxantrone: Modest activity in a Phase II trial in advanced prostate cancer.

CK Osborne;A Drelichman;DD Von Hoff;ED Crawford Cancer Treat Rep 67:1133-1135

Southwest Oncology Group Phase II studies with Mitoxantrone in nonhematologic malignancies.

RL Stephens;DD Von Hoff;SA Taylor;WA Knight III;RB Livingston;FE Bull;J Cowan;RD Hilgers;CK Osborne;GA Gates;G Clark In: New Anticancer Drugs: Mitoxantrone and Bisantrene . M Rozencweig, et al, eds. New York: Raven Press, 125-30

Cardiotoxicity in patients treated with Mitoxantrone on Southwest Oncology Group Phase II protocols.

GM Clark;LK Tokaz;DD Von Hoff;LL Thoi;CA Coltman Jr Cancer Treat Symp 3:25-30

A Phase II clinical investigation of dihydroxyanthracenedione (DHAD) in patients with advanced prostatic cancer.

A Drelichman;CK Osborne;DD Von Hoff ASCO #C-465

Southwest Oncology Group (SWOG) Phase II with mitoxantrone in non-hematologic malignancies.

RL Stephens;G Clark 3rd NCI-EORTC Symposium on New Drugs in Cancer Therapy (October 15-17, 1981), #36